ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0960

Serum C3 Level and Glucocorticoid Dose Are Risk Factors for Preterm Birth in Patients with Systemic Lupus Erythematosus

Hiromi Shimada1, Risa Wakiya1, shusaku nakashima2, Mikiya Kato1, taichi miyagi3, Yusuke Ushio4, Koichi Sugihara5, Rina Mino6, mao mizusaki6, Kanako Chujo7, Tomohiro Kameda1 and Hiroaki Dobashi8, 1Kagawa University, Kagawa, Japan, 2Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, 3Kagawa University, Kidagun, Japan, 4Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, 5Kagawa University, Miki-cho, Kita-gun, Japan, 6Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, 7Kagawa University, Miki, Kita District, Kagawa, Japan, 8Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Kagawa, Japan

Meeting: ACR Convergence 2022

Keywords: complement, glucocorticoids, pregnancy, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Women with Systemic lupus erythematosus (SLE) have more difficulty in achieving a successful pregnancy than healthy women, because of higher risks for adverse pregnancy outcomes (APOs) especially in preterm birth (1). Many reports revealed that preterm birth is related to uncontrolled high disease activity, including low complements and high titer of anti-double stranded DNA (dsDNA) antibody (2, 3). On the other hand, recently we reported that a relative lower dose of glucocorticoid dose (cut-off dose; 10mg/day) was significantly associated with preterm birth (4). However, it is not clarified whether disease activity parameters or glucocorticoid doses during pregnancy are at greater risk for preterm birth. Therefore, we aimed to identify which disease parameters or glucocorticoid dose may become risk factors for preterm birth.

Methods: We used the data of SLE patients who had been treated at the planning for pregnancy and gave birth from rheumatic disease pregnancy registry in our institution. We collected complement levels (C3, C4, CH50) and the titer of anti-dsDNA antibody at conception as immunological disease activity parameters and glucocorticoid dose during pregnancy. We retrospectively analyzed the association between preterm birth and disease activity parameters or glucocorticoid dose.

Results: The subjects were 60 pregnancies of 45 patients. Of all cases, preterm birth occurred in 14 cases (23.3%). Preterm birth was associated with C3 levels and the titers of anti-dsDNA antibody (P=0.03 and 0.01). On the other hand, it had no association with C4 and CH50 levels (P = 0.16 and 0.17). We performed logistic regression analysis for preterm birth, which showed that the cut-off of C3 level was 62 mg/dl and that of anti-dsDNA antibody titer was 5.4 IU/ml. We have already showed the cut-off of mean glucocorticoid dose for preterm birth was 10mg/day. Cases with C3 < 62mg/dl or anti-dsDNA antibody > 5.4IU/ml or mean glucocorticoid dose > 10mg/day had an increased risk of preterm birth (P = 0.01, 0.04, < 0.01, respectively, Figure 1). Additionally, gestational weeks at delivery were significantly shorter in these cases (P < 0.01, 0.01, < 0.01, respectively, Figure 1). Multivariate logistic regression analysis of risk factor for preterm birth was performed in Table 1. It showed that C3 < 62mg/dl or mean glucocorticoid dose > 10mg/day was a risk factor for preterm birth (P = 0.039 and 0.026). The combination of C3 < 62mg/dl and mean glucocorticoid dose > 10mg/day had a significantly higher rate of risk for preterm birth (P = 0.01), and significant difference of gestational weeks at delivery (P = 0.02, Figure 2).

Conclusion: In women with SLE, preterm birth is strongly associated with C3 levels and mean glucocorticoid doses. Therefore, it is important to manage both disease activity, especially in C3, and glucocorticoid dose in women who hope to conceive.

Supporting image 1

Figure 1. Comparison of the rate of preterm birth or gestational weeks at delivery with disease activity parameters and glucocorticoid doses. A. Rate of preterm birth. Cases with C3 < 62mg/dl or anti-dsDNA antibody titers > 5.4IU/ml or PSL > 10mg/day had a significantly higher rate of preterm birth (P = 0.01, 0.04 and <0.01). B. Gestational weeks at delivery. In cases with C3 < 62mg/dl or anti-dsDNA antibody titers > 5.4IU/ml or PSL > 10mg/day, gestational weeks at delivery were siginificantly shorter (P <0.01, 0.01 and <0.01). These analyses were based on Fisher’s exact test. PSL: prednisolone.

Supporting image 2

Table 1. Multivariate logistic regression analysis of risk factor for preterm birth. C3 < 62mg/dl or mean glucocorticoid dose > 10mg/day was shown to be a risk factor for preterm birth (P = 0.039 and 0.026).

Supporting image 3

Figure 2. Comparison of the rate of preterm birth or gestational weeks at delivery with the combination of C3 levels and glucocorticoid doses. The combination of C3 < 62mg/dl and PSL > 10mg/day had a significantly higher rate of risk for preterm birth (P = 0.01), and significant difference of gestational weeks at delivery (P = 0.02). These analyses were based on Fisher’s exact test. PSL: prednisolone.


Disclosures: H. Shimada, None; R. Wakiya, None; s. nakashima, None; M. Kato, None; t. miyagi, None; Y. Ushio, None; K. Sugihara, None; R. Mino, None; m. mizusaki, None; K. Chujo, None; T. Kameda, None; H. Dobashi, Bristol-Myers Squibb (BMS), Chugai, Eli Lilly, GlaxoSmithKlein (GSK), MSD, Novartis, Pfizer, UCB Pharma.

To cite this abstract in AMA style:

Shimada H, Wakiya R, nakashima s, Kato M, miyagi t, Ushio Y, Sugihara K, Mino R, mizusaki m, Chujo K, Kameda T, Dobashi H. Serum C3 Level and Glucocorticoid Dose Are Risk Factors for Preterm Birth in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/serum-c3-level-and-glucocorticoid-dose-are-risk-factors-for-preterm-birth-in-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-c3-level-and-glucocorticoid-dose-are-risk-factors-for-preterm-birth-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology